AM giant 3D Systems has announced a joint development partnership with biotech company CollPlant, a developer of proprietary bioink products (rhCollagen) for 3D bioprinting tissues. Working together, the companies will leverage 3D Systems expertise in 3D printing and healthcare applications and CollPlant’s deep knowledge of bioinks to jointly develop tissue and scaffold bioprinting processes for third party collaborators.
The partnership’s overall goal is to develop bioprinting technologies in order to advance regenerative medicine research. The companies are determined to create an integrated bioprinting solution (or solutions) targeted specifically at printing tissues and scaffolds for regenerative medicine applications.
Through the collaboration, 3D Systems and CollPlant will both have access to the former’s 3D printers and the latter’s BioInks, as well as new formulations of rhCollagen-based inks developed jointly by the companies. The combination of printing technology and materials can be leveraged for their own products as well as by third parties.
“3D Systems is excited to work with CollPlant to develop groundbreaking bioprinted tissue and scaffold technologies,” commented Chuck Hull, Co-Founder and CTO of 3D Systems. “We believe 3D printing to be a key technology for regenerative medicine, and this collaboration is one of many we are entering to play an integral role in this exciting field. Combining our innovative 3D printing technologies with CollPlant’s rhCollagen-based BioInks has the potential to make a significant impact in bioprinting and regenerative medicine.”
Yehiel Tal, CEO of CollPlant, added: ”We strongly believe that our proven rhCollagen is the finest building block for regenerative medicine tissues and scaffolds available today. As the leading additive manufacturing printing solutions company, 3D Systems is the perfect partner for us. Together, we can offer the best combined technology for 3D bioprinting. We are honored to have established this important collaboration and we look forward to working together to advance 3D bioprinting technology to the commercial phase.”